Combating PBM Rebate Structures: What New Healthcare Bills Mean for Pharma

Pharmacy Benefit Managers (PBMs) have become central intermediaries in the U.S. prescription-drug supply chain. They negotiate with pharmaceutical manufacturers, build formularies, manage pharmacy networks, and determine how rebates and other price concessions flow between manufacturers, health plans, pharmacies, and patients. That position has also made PBM compensation and rebate structures a growing focus of policymakers and regulators.

The policy landscape is now moving beyond proposals alone. The Consolidated Appropriations Act, 2026, enacted on February 3, 2026, added new PBM-related requirements under ERISA, including rebate pass-through and reporting provisions for certain employer health plans. Separately, the 2025 Pharmacy Benefit Manager Reform Act remains a proposed federal measure, while Medicare Part D PBM reforms enacted in 2026 are scheduled to apply beginning in 2028.

For pharmaceutical manufacturers, the result is a changing commercial environment in which PBM rebate reform increasingly affects pricing, contracting, forecasting, and market access strategy.

Anatomy of the Reform: Delinking and Rebate Pass-Throughs

The central idea behind current pharmaceutical rebate structures legislation is to reduce the financial connection between PBM compensation and the price or utilization of prescription drugs.

Delinking PBM compensation

For Medicare Part D, provisions enacted in 2026 require contracts beginning January 1, 2028, to limit PBM and affiliate remuneration for covered Part D utilization to qualifying bona fide service fees, subject to specified exceptions. A bona fide service fee is generally structured as a flat-dollar payment reflecting fair-market-value compensation for an itemized service actually performed rather than a payment calculated from drug price, rebates, formulary placement, or referral volume.

That distinction matters to manufacturers because percentage-based administrative payments can behave differently from fixed service fees. When compensation is connected to a drug’s list price, a higher-priced product can generate a larger payment even when the underlying service does not change.

Rebate pass-throughs

Pass-through requirements create another major shift. The 2026 ERISA amendments require certain PBM arrangements serving covered group health plans to address the remittance of rebates, fees, alternative discounts, and other remuneration. The Department of Labor has subsequently been developing regulatory guidance around implementation, disclosure, and audit procedures.

The commercial consequence is that manufacturers may need to reconsider how gross-to-net economics are modeled. A rebate that historically supported formulary access while being shared among multiple supply-chain participants cannot automatically be treated as a stable source of PBM economics under a stricter pass-through framework.

Transparency and audit requirements

Transparency is becoming equally important. CMS already requires reporting from PBMs serving qualified health plans on rebates, discounts, price concessions, prescription utilization, and amounts passed through to plans. Newer federal requirements add further scrutiny of compensation, affiliated entities, pharmacy relationships, and plan-level drug spending.

The practical direction is clear: manufacturers should expect greater visibility into where money moves after a product leaves the manufacturer’s commercial organization.

Strategic Implications for Pharmaceutical Manufacturers

For manufacturers, delinking PBM compensation drug pricing changes more than a contract clause. It can affect the economics used to determine list price, rebate depth, formulary strategy, and expected net revenue.

List price versus net price dynamics

Historically, manufacturers have sometimes used higher list prices alongside larger rebates to compete for favorable formulary treatment. The FTC has alleged that rebate-driven incentives contributed to this dynamic in insulin markets, including situations where higher-list-price products generated larger rebates while lower-list-price alternatives received less favorable treatment. These remain allegations in the agency’s enforcement proceedings rather than a universal description of every PBM arrangement.

If rebate economics become less important to PBM compensation, manufacturers may face stronger commercial pressure to demonstrate value through the product’s net economics rather than the size of the headline rebate.

That does not automatically mean list prices will fall. Pricing decisions will continue to depend on competition, clinical differentiation, payer mix, launch strategy, and the specific contracting environment.

Contracting and rebate structures

Market access teams will need to examine whether existing agreements clearly distinguish bona fide services from rebates, discounts, administrative payments, and other forms of remuneration.

Contracts should also be evaluated for provisions covering:

• Rebate calculation and payment timing
• Formulary placement requirements
• Administrative and data fees
• Fair-market-value documentation
• Audit rights
• Affiliate and rebate-aggregator arrangements
• Reporting obligations
• Changes triggered by federal or state law

The objective is not simply legal compliance. Contract architecture increasingly becomes part of commercial forecasting.

Formulary positioning

Formulary competition may also evolve. If back-end rebates become less central to preferred placement, manufacturers may need to rely more heavily on comparative net cost, clinical outcomes, adherence programs, utilization management arrangements, and evidence supporting the product’s overall value.

The FTC’s PBM investigations have highlighted the significance of formulary leverage and vertical integration in the prescription-drug supply chain. For manufacturers, that makes payer segmentation and channel-specific market access analysis more important than a single national rebate assumption.

Spillover Effects on Commercial Markets and Patient Affordability

PBM reform does not operate only at the manufacturer-PBM level. Its effects can extend to employer-sponsored plans, patients, pharmacies, and other participants in the prescription-drug market.

One important development is the growing federal focus on self-insured employer plans. The Department of Labor’s 2026 proposed PBM disclosure rule would require PBMs and certain affiliated service providers to disclose compensation and financial arrangements to fiduciaries of ERISA-covered self-insured plans, including manufacturer payments, spread compensation, pharmacy claw-backs, and price-protection arrangements.

However, rebate pass-through does not necessarily translate into an immediate one-for-one reduction in premiums or patient cost sharing. CBO’s analysis of the earlier Pharmacy Benefit Manager Reform Act estimated that PBM changes could reduce net retail drug costs while producing a much smaller effect on average employment-based insurance premiums. Actual outcomes will depend on plan design, contract negotiations, competition, and how savings are allocated.

The 340B environment adds another layer. HRSA announced a revised 340B rebate-model pilot in 2026, creating another mechanism for qualifying manufacturers to provide 340B ceiling-price benefits through rebates for selected drugs. These developments are separate from PBM reform but share a broader policy emphasis on transaction visibility and verification.

Meanwhile, independent pharmacies remain part of the debate. FTC investigations have examined PBM reimbursement practices, spread pricing, and vertical integration involving affiliated pharmacies.

Compliance, Legal Hurdles, and Industry Friction

Implementation will not be straightforward because the U.S. pharmacy-benefit market is governed by overlapping federal and state frameworks.

The ERISA question is particularly important for self-funded employer plans. State governments continue to regulate aspects of PBM conduct, but the interaction between state requirements and federally governed employee benefit plans can create preemption disputes. The Supreme Court’s decision in Rutledge v. Pharmaceutical Care Management Association established that ERISA does not categorically preempt state regulation simply because that regulation affects prescription-drug reimbursement. The precise application of federal and state requirements nevertheless remains fact-specific.

Federal oversight is also expanding. The Department of Labor is examining PBM compensation through the ERISA fiduciary and prohibited-transaction framework, while the FTC continues to scrutinize PBM competition, rebate practices, vertical integration, and affiliated pharmacy relationships.

The enforcement environment is already producing tangible changes. In 2026, the FTC reached settlements with Express Scripts and Caremark that included provisions addressing transparency, rebate economics, spread pricing, and the relationship between PBM fees and drug list prices.

For manufacturers, this means compliance teams should monitor not only legislation but also agency enforcement actions, proposed regulations, consent orders, and judicial decisions.

Practical Checklist for Pharma Market Access Teams

Pharmaceutical market access organizations should treat PBM reform as an ongoing commercial-planning issue rather than a one-time legal exercise.

1. Audit existing contracts

Review PBM and payer agreements for rebate definitions, administrative fees, data payments, performance guarantees, formulary provisions, audit rights, and affiliate arrangements. Identify provisions that may become difficult to defend or administer under emerging pass-through and disclosure standards.

2. Stress-test pricing models

Run scenarios involving lower rebate retention, reduced rebate guarantees, changing formulary economics, and potential list-price compression. Forecasting should separate gross sales, rebates, fees, discounts, and other gross-to-net components instead of treating them as one aggregate adjustment.

3. Upgrade data transparency

Commercial systems should be capable of reconciling contract terms with actual payments. Manufacturers may increasingly need product-level, payer-level, channel-level, and contract-level data to explain how a rebate or fee was calculated.

4. Align legal and commercial teams

Legal, finance, market access, pricing, government affairs, compliance, and contracting teams should share a common view of regulatory developments. State PBM laws, federal legislation, CMS guidance, DOL regulations, and FTC enforcement can affect the same commercial agreement from different directions.

5. Track implementation dates

Not every PBM reform takes effect immediately. For example, major Medicare Part D PBM remuneration and reporting provisions enacted in 2026 generally apply beginning in 2028. A compliance calendar should therefore distinguish enacted requirements from proposed legislation and future effective dates.

Framework for Evaluating Portfolio Exposure to PBM Reforms

A useful way to incorporate healthcare bills PBM impact pharma into portfolio planning is to score exposure by commercial characteristic rather than treating PBM reform as a uniform risk.

A weighted assessment can include:

A product heavily dependent on rebate-driven preferred placement would warrant closer contract review than a product whose competitive position is primarily based on clinical differentiation and relatively low rebate intensity.

The specialty channel deserves separate attention because PBM-affiliated pharmacies have become an important part of specialty-drug distribution. FTC staff reported that pharmacies affiliated with the three largest PBMs accounted for a substantial share of specialty-drug dispensing revenue and separately identified spread-pricing and dispensing-margin issues in specialty generic medicines.

The resulting exposure score should feed directly into long-range launch planning, price corridor analysis, contracting strategy, and scenario forecasting. Legislative forecasting is increasingly part of commercial planning—not simply government affairs.

Industry Red Flags and Strategic Missteps

Several assumptions can create unnecessary exposure as PBM reform develops.

Assuming historical rebate strategies will remain unchanged. A commercial model built around large rebates and preferred formulary placement may become less durable as transparency and compensation rules evolve.

Ignoring administrative-fee economics. If rebate-related compensation is reduced or restricted, PBMs may seek other sources of revenue. CBO has noted that PBM compensation can shift across different fee structures when particular revenue sources are regulated. Manufacturers should therefore model the total economics of the contract rather than focusing only on rebate percentages.

Overlooking vertical integration. A PBM may operate alongside an insurer, specialty pharmacy, mail-order pharmacy, rebate aggregator, or other affiliated business. Such structures can create additional disclosure, audit, contracting, and competition considerations.

Treating reform as only a legal issue. Legal compliance is necessary, but the commercial consequences reach pricing, forecasting, contracting, formulary strategy, channel management, and revenue recognition.

Failing to distinguish enacted requirements from proposals. The federal landscape contains enacted 2026 provisions, proposed rules, proposed legislation, and ongoing enforcement actions. Treating all of them as equivalent can lead to poor implementation timing and inaccurate forecasts.

Final Thoughts — Transparency as the New Baseline

PBM rebate reform is moving the pharmaceutical supply chain toward greater visibility into how drug prices, rebates, fees, and pharmacy payments interact. The shift is occurring through multiple channels: enacted federal legislation, proposed regulations, state-level requirements, and federal enforcement.

For pharmaceutical manufacturers, the practical response is not simply to reduce rebates. It is to understand the economics behind every major contracting mechanism and determine how those economics behave under different regulatory scenarios.

As transparency becomes a more important baseline, manufacturers will need stronger data, clearer contracts, defensible service-fee structures, and better evidence of product value. Companies that integrate regulatory forecasting with pricing and market access planning will be better positioned to adapt as PBM rules continue to evolve.